Brand Intelligence Graph
Company Overview
About Relay Therapeutics
Relay Therapeutics was founded in 2016 in Cambridge, Massachusetts, emerging from research at MIT and D.E. Shaw Research. The company is built around its Dynamo platform, which integrates computational protein motion modeling (molecular dynamics simulations) with structural biology and medicinal chemistry to design small-molecule drugs that exploit the dynamic conformational states of disease-relevant proteins—a dimension traditional structure-based drug design ignores.
Business Model & Competitive Advantage
Relay's lead program, RLY-2608, is a first-in-class allosteric, mutant-selective PI3Kα inhibitor for advanced breast cancer patients with PI3KCA mutations. Unlike approved PI3Kα inhibitors that cause metabolic toxicity by inhibiting wild-type PI3Kα in normal tissues, RLY-2608 selectively targets the mutant form. The compound has shown early clinical promise including objective responses in patients who progressed on prior alpelisib, supporting a differentiated profile. Additional programs target FGFR2 and SHP2 in solid tumors.
Competitive Landscape 2025–2026
Relay has raised over $1.2 billion in equity financing and holds substantial cash reserves. The company is conducting multiple clinical trials and building a pipeline that validates its Dynamo-guided discovery approach. Though revenue-stage remains early, Relay represents a leading example of next-generation computational oncology companies seeking to turn protein dynamics insights into selective, differentiated medicines.
Key Differentiators
Emerging Innovator
Relay Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Earendil Labs
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Iambic Therapeutics
Iambic Therapeutics was founded in 2019 with the mission of applying AI-driven drug discovery to oncology — one of the most complex and high-value areas of pharmaceutical development. The company buil
Xaira Therapeutics
Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated by Arch Venture Par
Converge Bio
Converge Bio is an Israeli AI drug discovery company using machine learning to design and optimize small molecule therapeutics across a broad portfolio of programs. Founded by a team with deep experti
Isomorphic Labs
Isomorphic Labs is an Alphabet company spun out of Google DeepMind to apply AI to the full drug discovery pipeline, from target identification through molecular design and clinical candidate selection
Compare Relay Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Relay Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Relay Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Relay Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →